Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.
Huguet F, Chevret S, Leguay T, Thomas X, Boissel N, Escoffre-Barbe M, Chevallier P, Hunault M, Vey N, Bonmati C, Lepretre S, Marolleau JP, Pabst T, Rousselot P, Buzyn A, Cahn JY, Lhéritier V, Béné MC, Asnafi V, Delabesse E, Macintyre E, Chalandon Y, Ifrah N, Dombret H; Group of Research on Adult ALL (GRAALL). Huguet F, et al. Among authors: rousselot p. J Clin Oncol. 2018 Aug 20;36(24):2514-2523. doi: 10.1200/JCO.2017.76.8192. Epub 2018 Jun 4. J Clin Oncol. 2018. PMID: 29863974 Free article. Clinical Trial.
Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Réflexion en Hématologie.
Gardin C, Chaibi P, de Revel T, Rousselot P, Turlure P, Micléa JM, Nédellec G, Dombret H. Gardin C, et al. Among authors: rousselot p. Leukemia. 1997 Jan;11(1):16-21. doi: 10.1038/sj.leu.2400536. Leukemia. 1997. PMID: 9001413 Clinical Trial.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H, Vekhoff A, Cony-Makhoul P, Leblond V, Troussard X, Cordonnier C, de Revel T, Simon M, Nicolini F, Stoppa AM, Janvier M, Bordessoule D, Rousselot P, Ffrench M, Marie JP, Archimbaud E. Thomas X, et al. Among authors: rousselot p. Leukemia. 1999 Aug;13(8):1214-20. doi: 10.1038/sj.leu.2401474. Leukemia. 1999. PMID: 10450749 Clinical Trial.
Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients.
Morschhauser F, Cayuela JM, Martini S, Baruchel A, Rousselot P, Socié G, Berthou P, Jouet JP, Straetmans N, Sigaux F, Fenaux P, Preudhomme C. Morschhauser F, et al. Among authors: rousselot p. J Clin Oncol. 2000 Feb;18(4):788-94. doi: 10.1200/JCO.2000.18.4.788. J Clin Oncol. 2000. PMID: 10673520
Primary plasma cell leukaemia: a report of 18 cases.
Costello R, Sainty D, Bouabdallah R, Fermand JP, Delmer A, Diviné M, Marolleau JP, Gastaut JA, Olive D, Rousselot P, Chaïbi P. Costello R, et al. Among authors: rousselot p. Leuk Res. 2001 Feb;25(2):103-7. doi: 10.1016/s0145-2126(00)00102-8. Leuk Res. 2001. PMID: 11166824 Review.
In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia.
Galmarini CM, Thomas X, Calvo F, Rousselot P, Rabilloud M, El Jaffari A, Cros E, Dumontet C. Galmarini CM, et al. Among authors: rousselot p. Br J Haematol. 2002 Jun;117(4):860-8. doi: 10.1046/j.1365-2141.2002.03538.x. Br J Haematol. 2002. PMID: 12060121 Free article.
308 results